These results suggest that AZA decreases intracellular ROS levels and increases the antioxidant capacity by upregulating Prdx2 and Prdx3, thus maintaining the redox balance and further suppressing AML in vitro and in vivo. Here, PRDX2 is linked to acute myeloid leukemia.